Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Dynamics and Prognostic Impact of Peripheral Blood Blast Clearance in Patients with Acute Myeloid Leukemia (AML) Receiving FLT3 Inhibitor Therapy in Combination with Induction Chemotherapy

Christopher B. Benton, MD, Peng Qiu, PhD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Sherry A. Pierce, RN, BS, Anisha Borthakur, Marina Konopleva, MD, PhD, Jorge E. Cortes, MD, Michael Andreeff, MD, PhD, Alfonso Quintás-Cardama, M.D.

Blood (2012) 120 (21): 1417.

https://doi.org/10.1182/blood.V120.21.1417.1417

Published: 2012

Journal Articles

Outcomes of Patients (pts) with Myelodysplatic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure

Hady Ghanem, MD, Guillermo Garcia Manero, MD, Stefan Faderl, MD, Koichi Takahashi, MD, Farhad Ravandi, Jorge E. Cortes, MD, Susan O'Brien, M.D., Naval G. Daver, MD, Lakshmikanth Katragadda, MD, Naveen Pemmaraju, M.D., Sherry A. Pierce, RN, BS, Alfonso Quintás-Cardama, MD, Tapan M. Kadia, M.D., Hagop M. Kantarjian, MD, Elias J. Jabbour, MD

Blood (2012) 120 (21): 1722.

https://doi.org/10.1182/blood.V120.21.1722.1722

Published: 2012

Journal Articles

Biphenotypic Blast Phase (B-BP) of Chronic Myeloid Leukemia (CML): A Single Institution Experience

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Elias Jabbour, Lakshmikanth Katragadda, MD, Jorge E. Cortes, MD, Naveen Pemmaraju, M.D., Alfonso Quintás-Cardama, M.D.

Blood (2012) 120 (21): 1687.

https://doi.org/10.1182/blood.V120.21.1687.1687

Published: 2012

Journal Articles

The Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Outside of a Clinical Trial or On a Clinical Trial At a Single Institution

Musa Yilmaz, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Susan M. O'Brien, MD, Gautam Borthakur, M.D., Srdan Verstovsek, MD, PhD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Jan A. Burger, MD, PhD, Sherry A. Pierce, RN, BS, Alfonso Quintás-Cardama, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 1693.

https://doi.org/10.1182/blood.V120.21.1693.1693

Published: 2012

Journal Articles

Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21

Paolo Strati, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Farhad Ravandi, MD, Naveen Pemmaraju, M.D., Guillermo Garcia-Manero, MD, Tapan M. Kadia, M.D., Elias J. Jabbour, MD, Aziz Nazha, Gautam Borthakur, Stefan Faderl, MD, Alfonso Quintás-Cardama, MD, Naval G. Daver, MD

Blood (2012) 120 (21): 1488.

https://doi.org/10.1182/blood.V120.21.1488.1488

Published: 2012

Journal Articles

Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) After Surviving 5 Years of Initial Therapy with Interferon Alpha (IFN), Imatinib (IMA) or Allogeneic Stem Cell Transplantation (ASCT)

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Richard E. Champlin, Lakshmikanth Katragadda, MD, Gabriela Rondon, MD, Elias J. Jabbour, MD, Alfonso Quintás-Cardama, MD, Sherry A. Pierce, RN, BS, Jorge E. Cortes, MD

Blood (2012) 120 (21): 2001.

https://doi.org/10.1182/blood.V120.21.2001.2001

Published: 2012

Journal Articles

Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML)

Koichi Takahashi, MD, Naveen Pemmaraju, M.D., Miloslav Beran, Alfonso Quintás-Cardama, M.D., Jorge E. Cortes, MD, Farhad Ravandi, MD, Stefan Faderl, MD, Srdan Verstovsek, MD, PhD, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., Elias J. Jabbour, MD, Naval Daver, MD, Zeev Estrov, MD, PhD, Sherry A. Pierce, RN, BS, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3797.

https://doi.org/10.1182/blood.V120.21.3797.3797

Published: 2012

Journal Articles

Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)

Aziz Nazha, Hagop M. Kantarjian, MD, Preetesh Jain, MD, DM, PhD, Elias J. Jabbour, MD, Alfonso Quintás-Cardama, M.D., Rajyalakshmi Luthra, PhD, Lynne V. Abruzzo, MD, PhD, Gautam Borthakur, M.D., Farhad Ravandi, MD, Sherry A. Pierce, RN, BS, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3757.

https://doi.org/10.1182/blood.V120.21.3757.3757

Published: 2012

Journal Articles

Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome

Alfonso Quintás-Cardama, M.D., Hagop M. Kantarjian, MD, Farhad Ravandi, Cielo Foudray, Naveen Pemmaraju, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., Naval G. Daver, MD, Stefan Faderl, MD, Elias Jabbour, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD

Blood (2012) 120 (21): 3821.

https://doi.org/10.1182/blood.V120.21.3821.3821

Published: 2012

Journal Articles

Response to Frontline Therapy with Second Generation Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Analysis of Outcome for b3a2 Vs. b2a2 Fusion Transcripts

Carlos G. Romo, M.D., Hagop M Kantarjian, M.D., Rajyalakshmi Luthra, Ph.D., Alfonso Quintás-Cardama, M.D., Elias J. Jabbour, MD, Gautam Borthakur, M.D., Tapan M. Kadia, M.D., Farhad Ravandi, MD, Naveen Pemmaraju, M.D., Sherry A. Pierce, RN, BS, Susan O'Brien, M.D., Jorge E. Cortes, MD

Blood (2012) 120 (21): 3781.

https://doi.org/10.1182/blood.V120.21.3781.3781

Published: 2012

Journal Articles

Prognostic Factors in the Blastic and Accelerated Phase of Patients with Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era

Young Kwang Chae, MD, MPH, Hagop M. Kantarjian, MD, Carlos G. Romo, M.D., Clay Whitaker, Elias J. Jabbour, MD, Susan O'Brien, M.D., Gautam Borthakur, M.D., Farhad Ravandi, MD, Deborah A. Thomas, MD, Sherry A. Pierce, RN, BS, Alfonso Quintás-Cardama, M.D., Jorge E. Cortes, MD

Blood (2012) 120 (21): 3786.

https://doi.org/10.1182/blood.V120.21.3786.3786

Published: 2012

Journal Articles

Patient (Pt)-Driven Discontinuation of Tyrosine Kinase Inhibitor Theray in Chronic Phase Chronic Myeloid Leukemia (CML) - Single Institution Experience

Ohad Benjamini, MD, Hagop M. Kantarjian, MD, Mary Beth Rios, RN, Elias Jabbour, MD, Susan O'Brien, M.D., Preetesh Jain, MD, DM, PhD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Gautam Borthakur, M.D., Alfonso Quintás-Cardama, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3783.

https://doi.org/10.1182/blood.V120.21.3783.3783

Published: 2012

Journal Articles

A Phase II Study of Methotrexate (M), Vincristine (O), Pegylated L-Asparaginase (pA), and Dexamethasone (MOpAD) in Patients with Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

Tapan M. Kadia, MD, Jorge E. Cortes, MD, Deborah Thomas, MD, Farhad Ravandi, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Alfonso Quintás-Cardama, MD, Melanie Baccus, RN, Rebecca Garris, BSc, Elias J. Jabbour, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD

Blood (2012) 120 (21): 4308.

https://doi.org/10.1182/blood.V120.21.4308.4308

Published: 2012

Journal Articles

Incidence and Outcomes of Chronic Myeloid Leukemia (CML) Patients (pts) with Other Chromosomal Abnormalities (OCA) Treated with Second Generation Tyrosine Kinase Inhibitors (TKI)

Naveen Pemmaraju, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Alfonso Quintás-Cardama, MD, Gautam Borthakur, MD, Elizabeth M Burton, Sara E Dellasala, RN, Sherry A. Pierce, RN, BS, Steven M. Kornblau, MD, PhD, Srdan Verstovsek, MD, PhD, Susan O'Brien, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 4311.

https://doi.org/10.1182/blood.V120.21.4311.4311

Published: 2012

Journal Articles

Cytogenetic and Molecular Characterization of Genitourinary Extramedullary Disease in Acute Myeloid Leukemia

Kathy M. Tran, Hagop M. Kantarjian, MD, Syed M. Kazmi, MD, Alfonso Quintás-Cardama, MD, Jorge E. Cortes, MD, Zeev Estrov, MD, Maro Ohanian, DO, Tapan M. Kadia, M.D., Gautam Borthakur, M.D., Farhad Ravandi, MD, Naveen Pemmaraju, M.D.

Blood (2012) 120 (21): 4326.

https://doi.org/10.1182/blood.V120.21.4326.4326

Published: 2012

Journal Articles

Natural History and Potential for Cure of Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Therapy with Recombinant Interferon-Alfa: 30-Year Update From M.D. Anderson Cancer Center

Alfonso Quintás-Cardama, M.D., Hagop M. Kantarjian, MD, Susan O'Brien, M.D., Elias J. Jabbour, MD, Guillermo Garcia-Manero, MD, Charles Koller, MD, Sherry A. Pierce, RN, BS, Moshe Talpaz, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 918.

https://doi.org/10.1182/blood.V120.21.918.918

Published: 2012

Journal Articles

Nomogram to Prognosticate Outcomes in Patients with Chronic Myeloid Leukemia At Any Time-Point During Tyrosine Kinase Inhibitor Therapy

Alfonso Quintás-Cardama, M.D., Xuelin Huang, PhD, Sangbum Choi, PhD, Hagop M Kantarjian, M.D., Jorge E. Cortes, MD

Blood (2012) 120 (21): 71.

https://doi.org/10.1182/blood.V120.21.71.71

Published: 2012

Journal Articles

The Average Baseline BCR-ABL Levels Are Significantly Higher in Patients with Resistance to Dasatinib As First-Line Treatment for Early Chronic Phase Chronic Myeloid Leukemia

Cristian Tomasetti, PhD, Hagop M. Kantarjian, MD, Ritesh Ramchandani, Elias Jabbour, MD, Alfonso Quintás-Cardama, MD, Giovanni Parmigiani, PhD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 4436.

https://doi.org/10.1182/blood.V120.21.4436.4436

Published: 2012

Journal Articles

Rare Blast Phase (BP) Phenotypes of Chronic Myeloid Leukemia (CML)

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Elias J. Jabbour, MD, Jorge E. Cortes, MD, Alfonso Quintás-Cardama, MD

Blood (2012) 120 (21): 4434.

https://doi.org/10.1182/blood.V120.21.4434.4434

Published: 2012

Journal Articles

Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP)

Hady Ghanem, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Naveen Pemmaraju, M.D., Stefan Faderl, MD, Sara E Dellasala, RN, Susan M. O'Brien, MD, Jan A. Burger, MD, PhD, Gautam Borthakur, M.D., Tapan M. Kadia, M.D., Alfonso Quintás-Cardama, MD, Mark Brandt, BS, Sherry A. Pierce, RN, BS, Guillermo Garcia-Manero, MD, Elias J. Jabbour, MD

Blood (2012) 120 (21): 4939.

https://doi.org/10.1182/blood.V120.21.4939.4939

Published: 2012

NARROW

Dynamics and Prognostic Impact of Peripheral Blood Blast Clearance in Patients with Acute Myeloid Leukemia (AML) Receiving FLT3 Inhibitor Therapy in Combination with Induction Chemotherapy

Outcomes of Patients (pts) with Myelodysplatic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML) Post Clofarabine Failure

Biphenotypic Blast Phase (B-BP) of Chronic Myeloid Leukemia (CML): A Single Institution Experience

The Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Imatinib Outside of a Clinical Trial or On a Clinical Trial At a Single Institution

Biological and Clinical Features of Patients with Acute Myeloid Leukemia Bearing Trisomy 21

Outcomes of Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients (pts) After Surviving 5 Years of Initial Therapy with Interferon Alpha (IFN), Imatinib (IMA) or Allogeneic Stem Cell Transplantation (ASCT)

Refined MD Anderson Prognostic Scoring System (MDAPS-R) for Chronic Myelomonocytic Leukemia (CMML)

Disease Patterns for Patients (pts) with Chronic Myeloid Leukemia (CML) That Have BCR-ABL Transcript Levels > 10% At 3 Month of Therapy with Tyrosine Kinase Inhibitors (TKIs)

Very High Rates of Clinical and Cytogenetic Response with the Combination of the Histone Deacetylase Inhibitor Pracinostat (SB939) and 5-Azacitidine in High-Risk Myelodysplastic Syndrome

Response to Frontline Therapy with Second Generation Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Analysis of Outcome for b3a2 Vs. b2a2 Fusion Transcripts

Prognostic Factors in the Blastic and Accelerated Phase of Patients with Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era

Patient (Pt)-Driven Discontinuation of Tyrosine Kinase Inhibitor Theray in Chronic Phase Chronic Myeloid Leukemia (CML) - Single Institution Experience

A Phase II Study of Methotrexate (M), Vincristine (O), Pegylated L-Asparaginase (pA), and Dexamethasone (MOpAD) in Patients with Relapsed and/or Refractory Acute Lymphoblastic Leukemia (ALL)

Incidence and Outcomes of Chronic Myeloid Leukemia (CML) Patients (pts) with Other Chromosomal Abnormalities (OCA) Treated with Second Generation Tyrosine Kinase Inhibitors (TKI)

Cytogenetic and Molecular Characterization of Genitourinary Extramedullary Disease in Acute Myeloid Leukemia

Natural History and Potential for Cure of Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Therapy with Recombinant Interferon-Alfa: 30-Year Update From M.D. Anderson Cancer Center

Nomogram to Prognosticate Outcomes in Patients with Chronic Myeloid Leukemia At Any Time-Point During Tyrosine Kinase Inhibitor Therapy

The Average Baseline BCR-ABL Levels Are Significantly Higher in Patients with Resistance to Dasatinib As First-Line Treatment for Early Chronic Phase Chronic Myeloid Leukemia

Rare Blast Phase (BP) Phenotypes of Chronic Myeloid Leukemia (CML)

Twice Daily Fludarabine and Cytarabine Combination (BID-FA) Is Effective in Pts with De Novo Acute Myeloid Leukemia (AML), Relapsed/Refractory (R/R) AML, High-Risk Myelodysplastic Syndromes (MDS), and Blast Phase Chronic Myeloid Leukemia (CML-BP)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only